Biotech founder dedicated to revolutionize healthcare with early disease detection, to enhance treatment success, minimize patient side effects, and save lives.
HK-Dtech Limited does develop and manufacture ultra-high performance fluorescent nanoparticles to significantly enhance biomarkers detection.
Our products serve the scientific research and medical diagnostics sectors by offering superior detection sensitivity, with user-friendly protocols and based on a cost-effective technology, making it an invaluable tool for advancing medical diagnostic and scientific discovery.
Our versatile nanoparticles extend beyond medical applications, with immense potential in environment, food safety, and energy sectors, positioning our company as a future global leader in detection and marking technologies.
Thanks to our two entities, located in France and in Hong Kong, we are supporting a global vision of transformative impact across multiple industries, promising substantial growth and market leadership.
After 15 years as a co-founder of retail and wholesale businesses, mainly across Asia, and Africa, I sought a career shift to create meaningful, global impact.
In 2018, I invested in Poly-Dtech SAS, and in 2019, co-founded HK-Dtech Limited, both pioneering biotech firms focused on revolutionizing healthcare through early disease detection.
Our mission is to transform disease diagnosis by developing cutting-edge biomarkers that enhance treatment success, minimize patient side effects, and save lives.
We aim to deliver unmatched performance in detection—faster, more accurate, and cost-effective than traditional methods. By leveraging innovative technology, we address critical gaps in healthcare, ensuring timely interventions and improved outcomes.
This transition reflects my commitment to merging entrepreneurial experience with purpose-driven innovation, ultimately advancing global health and accessibility.